Quantification of indirect pathway inhibition by the adenosine A2a antagonist SYN115 in Parkinson disease

Autor: Bandak Stephen I, Jonathan M. Koller, Kevin J. Black, Meghan C. Campbell, Debra A Gusnard

Adenosine A2areceptor antagonists reduce symptom severity in Parkinson disease (PD) and animal models. Rodent studies support the hypothesis that A2aantagonists produce this benefit by reducing the inhibitory output of the basal ganglia indirect path

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9945fec89c51ef92adbb3a0831ba71d4
https://europepmc.org/articles/PMC3008651/

Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease.

Autor: Black, Kevin J., Koller, Jonathan M., Campbell, Meghan C., Gusnard, Debra A., Bandak, Stephen I.

Publikováno v: Journal of Neuroscience; 12/1/2010, Vol. 30 Issue 48, p16284-16292, 9p, 4 Diagrams, 2 Charts

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Increased Orbitofrontal Brain Activation after Administration of a Selective Adenosine A(2A) Antagonist in Cocaine Dependent Subjects.

Autor: Moeller FG; Department of Psychiatry and Behavioral Sciences, Center for Neurobehavioral Research on Addiction, University of Texas Health Science Center at Houston Houston, TX, USA., Steinberg JL, Lane SD, Kjome KL, Ma L, Ferre S, Schmitz JM, Green CE, Bandak SI, Renshaw PF, Kramer LA, Narayana PA

Publikováno v: Frontiers in psychiatry [Front Psychiatry] 2012 May 28; Vol. 3, pp. 44. Date of Electronic Publication: 2012 May 28 (Print Publication: 2012).